Preclinical studies suggested that darapladib could reduce Lp-PLA2 and Rho kinase activity, lower inflammatory markers (such as CRP), improve nitric oxide production, and reduce cardiomyocyte apoptosis in animal models of atherosclerosis [205]. The gene discussed is PLA2G7; the disease is atherosclerosis.